Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The efficacy and safety of dual-target rTMS over dorsolateral prefrontal cortex (DLPFC) and cerebellum in the treatment of negative symptoms in first-episode schizophrenia: Protocol for a multicenter, randomized, double-blind, sham-controlled study.
Schizophr Res Cogn
March 2025
Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai 200030,China.
Background And Objective: The dorsolateral prefrontal cortex (DLPFC) - cerebellum circuit has been implicated in the pathogenesis of negative symptoms of schizophrenia (SZ). Both areas are considered separate targets for repetitive transcranial magnetic stimulation (rTMS) treatment, showing potential for improving negative symptoms. However, there is still a lack of research that targets both DLPFC and cerebellum simultaneously.
View Article and Find Full Text PDFThe effects of chemogenetic targeting of serotonin-projecting pathways on L-DOPA-induced dyskinesia and psychosis in a bilateral rat model of Parkinson's disease.
Front Neural Circuits
December 2024
Department of Psychology, Binghamton University, Binghamton, NY, United States.
Introduction: Parkinson's disease (PD) is commonly characterized by severe dopamine (DA) depletion within the substantia nigra (SN) leading to a myriad of motor and non-motor symptoms. One underappreciated and prevalent non-motor symptom, Parkinson's disease-associated psychosis (PDAP), significantly erodes patient and caregiver quality of life yet remains vastly understudied. While the gold standard pharmacotherapy for motor symptoms Levodopa (LD) is initially highly effective, it can lead to motor fluctuations like LD-induced dyskinesia (LID) and non-motor fluctuations such as intermittent PDAP.
View Article and Find Full Text PDFAcceptability, tolerability and safety of the BRIGhTMIND trial: Connectivity-guided intermittent theta-burst stimulation versus F3- repetitive transcranial magnetic stimulation for treatment-resistant depression.
Compr Psychiatry
January 2025
Nottingham National Institute for Health and Care Research (NIHR) Biomedical Research Centre, Nottingham, United Kingdom; Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, United Kingdom; Mental Health and Clinical Neurosciences, School of Medicine, University of Nottingham, Nottingham, United Kingdom. Electronic address:
Background: The BRIGhTMIND study was a double-blind RCT comparing repetitive transcranial magnetic stimulation at a standard simulation site (the "F3" location given by the International 10-20 system, F3-rTMS) versus connectivity-guided intermittent theta burst stimulation (cgiTBS) for treatment-resistant depression. This present study reports the acceptability, safety, and tolerability of F3-rTMS versus cgiTBS.
Methods: The present study used quantitative and qualitative methods.
Theta Burst Stimulation Protocols for Schizophrenia: A Systematic Review and Network Meta-Analysis.
JAMA Netw Open
October 2024
Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Importance: To date, several theta burst stimulation (TBS) protocols, such as intermittent TBS (iTBS), have been proposed; however, previous systematic reviews have revealed inconsistent efficacy findings in individual TBS studies for schizophrenia.
Objective: To examine which TBS protocols are associated with the most favorable and acceptable outcomes in adults with schizophrenia.
Data Sources: The Cochrane Library, PubMed, and Embase databases were searched for studies published before May 22, 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!